JP2019534330A5 - - Google Patents

Download PDF

Info

Publication number
JP2019534330A5
JP2019534330A5 JP2019545869A JP2019545869A JP2019534330A5 JP 2019534330 A5 JP2019534330 A5 JP 2019534330A5 JP 2019545869 A JP2019545869 A JP 2019545869A JP 2019545869 A JP2019545869 A JP 2019545869A JP 2019534330 A5 JP2019534330 A5 JP 2019534330A5
Authority
JP
Japan
Prior art keywords
pharmaceutical composition
composition according
dosage form
polyglutamic acid
tumor
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Granted
Application number
JP2019545869A
Other languages
English (en)
Japanese (ja)
Other versions
JP7083835B2 (ja
JP2019534330A (ja
Filing date
Publication date
Priority claimed from SG10201609131YA external-priority patent/SG10201609131YA/en
Application filed filed Critical
Publication of JP2019534330A publication Critical patent/JP2019534330A/ja
Publication of JP2019534330A5 publication Critical patent/JP2019534330A5/ja
Priority to JP2022089345A priority Critical patent/JP7466822B2/ja
Application granted granted Critical
Publication of JP7083835B2 publication Critical patent/JP7083835B2/ja
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

JP2019545869A 2016-11-01 2017-10-31 亜鉛-γ-PGA組成物およびがんを処置するための方法 Active JP7083835B2 (ja)

Priority Applications (1)

Application Number Priority Date Filing Date Title
JP2022089345A JP7466822B2 (ja) 2016-11-01 2022-06-01 亜鉛-γ-PGA組成物およびがんを処置するための方法

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
SG10201609131Y 2016-11-01
SG10201609131YA SG10201609131YA (en) 2016-11-01 2016-11-01 Zinc-pga compositions and methods for treating cancer
PCT/SG2017/050545 WO2018084806A1 (en) 2016-11-01 2017-10-31 ZINC-γ-PGA COMPOSITIONS AND METHODS FOR TREATING CANCER

Related Child Applications (1)

Application Number Title Priority Date Filing Date
JP2022089345A Division JP7466822B2 (ja) 2016-11-01 2022-06-01 亜鉛-γ-PGA組成物およびがんを処置するための方法

Publications (3)

Publication Number Publication Date
JP2019534330A JP2019534330A (ja) 2019-11-28
JP2019534330A5 true JP2019534330A5 (cg-RX-API-DMAC7.html) 2020-12-10
JP7083835B2 JP7083835B2 (ja) 2022-06-13

Family

ID=60327362

Family Applications (2)

Application Number Title Priority Date Filing Date
JP2019545869A Active JP7083835B2 (ja) 2016-11-01 2017-10-31 亜鉛-γ-PGA組成物およびがんを処置するための方法
JP2022089345A Active JP7466822B2 (ja) 2016-11-01 2022-06-01 亜鉛-γ-PGA組成物およびがんを処置するための方法

Family Applications After (1)

Application Number Title Priority Date Filing Date
JP2022089345A Active JP7466822B2 (ja) 2016-11-01 2022-06-01 亜鉛-γ-PGA組成物およびがんを処置するための方法

Country Status (10)

Country Link
US (2) US11944640B2 (cg-RX-API-DMAC7.html)
EP (1) EP3534914B1 (cg-RX-API-DMAC7.html)
JP (2) JP7083835B2 (cg-RX-API-DMAC7.html)
KR (1) KR102616690B1 (cg-RX-API-DMAC7.html)
CN (2) CN108014131B (cg-RX-API-DMAC7.html)
AU (2) AU2017354787B2 (cg-RX-API-DMAC7.html)
CA (1) CA3042383A1 (cg-RX-API-DMAC7.html)
MX (2) MX395613B (cg-RX-API-DMAC7.html)
SG (3) SG10201609131YA (cg-RX-API-DMAC7.html)
WO (1) WO2018084806A1 (cg-RX-API-DMAC7.html)

Families Citing this family (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
SG10201609131YA (en) 2016-11-01 2018-06-28 Xylonix Ip Holdings Pte Ltd Zinc-pga compositions and methods for treating cancer
SG10201708886RA (en) * 2017-10-30 2019-05-30 Xylonix Ip Holdings Pte Ltd α-PGA-ZINC COMPOSITIONS AND METHODS FOR TREATING CANCER
KR20210024065A (ko) * 2018-06-22 2021-03-04 자일로닉스 아이피 홀딩스 피티이. 엘티디. 아연 제제를 이용한 종양학 치료
KR102094182B1 (ko) * 2018-06-28 2020-03-30 주식회사 알랙스탠드 아연 함유 수용성 폴리글루타믹산 복합체 조성물
CA3214081A1 (en) 2021-03-18 2022-09-22 Xylonix Pte. Ltd Pharmaceutical polymer conjugates

Family Cites Families (44)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US2897122A (en) 1956-10-04 1959-07-28 Frosst & Co Charles E Enteric coated product
JP2712583B2 (ja) 1989-06-28 1998-02-16 味の素株式会社 易吸収性ミネラル含有飲食物
JP3551149B2 (ja) 1992-03-24 2004-08-04 味の素株式会社 易吸収性ミネラル含有組成物及びそれを含有する飲食品
EP0605757B1 (en) 1992-11-25 2001-08-16 Ajinomoto Co., Inc. Compositions and goods containing minerals and poly-gamma-glutamic acid
US5447732A (en) 1992-11-25 1995-09-05 Ajinomoto Co., Inc. High-absorption mineral-containing composition and foods
IL115156A (en) 1994-09-06 2000-07-16 Univ Georgia Pharmaceutical compositions for the treatment of cancer comprising 1-(2-hydroxymethyl-1,3-dioxolan-4-yl) cytosines
ITMI950515A0 (it) 1995-03-16 1995-03-16 Valpharma Sa Formulazioni gastroresistenti contenenti zinco
US6441025B2 (en) 1996-03-12 2002-08-27 Pg-Txl Company, L.P. Water soluble paclitaxel derivatives
JPH11313618A (ja) 1998-05-06 1999-11-16 Yoshio Inoue 胃にやさしい家畜用ミネラル(亜鉛)製剤及びその製造法
US6462075B1 (en) 1999-12-23 2002-10-08 The University Of Georgia Research Foundation, Inc. Chalcone and its analogs as agents for the inhibition of angiogensis and related disease states
US20020061599A1 (en) 1999-12-30 2002-05-23 Elling Christian E. Method of identifying ligands of biological target molecules
WO2003061598A2 (en) 2002-01-25 2003-07-31 The University Of Georgia Research Foundation, Inc. Solenopsin a, b and analogs as novel angiogenesis inhibitors
WO2004080210A1 (en) 2003-03-14 2004-09-23 Boehringer Ingelheim Danmark A/S Compositions of dietary metals for support of the physiological intestinal development and prevention of diarrhoea
KR100498812B1 (ko) 2003-07-10 2005-07-01 주식회사 바이오리더스 초고분자량의 폴리감마글루탐산을 함유하는 미네랄의 체내흡수 촉진용 조성물
JP4457641B2 (ja) 2003-11-10 2010-04-28 味の素株式会社 ゼラチンカプセル
JP5162812B2 (ja) 2004-07-08 2013-03-13 大正製薬株式会社 亜鉛含有経口投与用組成物
NZ563686A (en) 2005-06-07 2011-07-29 Univ Yale Methods of treating cancer and other conditions or disease states using LFMAU and LDT
AU2006257815A1 (en) * 2005-06-10 2006-12-21 Bipar Sciences, Inc. PARP modulators and treatment of cancer
WO2007043606A1 (ja) 2005-10-12 2007-04-19 Genolac Bl Corporation アニオン性ポリアミノ酸/金属複合体からなる抗糖尿病薬剤
US7528125B2 (en) 2006-03-20 2009-05-05 Jonathan L. Sessler Water-soluble zinc ionophores, zinc chelators, and/or zinc complexes and use for treating cancer
CN101674852A (zh) 2007-04-10 2010-03-17 日东电工株式会社 多功能聚谷氨酸盐药物载体
AU2008251836A1 (en) 2007-05-09 2008-11-20 Salutria Pharmaceuticals, Llc Spiro compounds for treatment of inflammatory disorders
CN101707869A (zh) 2007-05-09 2010-05-12 日东电工株式会社 具有多种药物的聚谷氨酸盐结合物和聚谷氨酸盐-氨基酸结合物
CA2756942C (en) 2009-04-10 2019-01-08 Cypress Pharmaceuticals, Inc. Phosphate-binding magnesium salts and uses thereof
JO3635B1 (ar) 2009-05-18 2020-08-27 Millennium Pharm Inc مركبات صيدلانية صلبة وطرق لانتاجها
CN101716180B (zh) 2009-11-06 2013-04-24 广西强寿药业集团有限公司 一种组合补充锌、钙药物及其制备方法
US20110117210A1 (en) 2009-11-17 2011-05-19 Andrey Ugolkov Therapeutic treatment of human cancers using simple salts of zinc
AU2011225810B2 (en) 2010-03-10 2014-11-06 Lupin Limited Rifaximin ready-to-use suspension
RU2609833C2 (ru) 2011-09-13 2017-02-06 Фармасайкликс Элэлси Лекарственные формы ингибитора гистондиацетилазы в комбинации с бендамутином и их применение
CA2892049C (en) 2012-11-21 2018-09-11 KBS Research, LLC Herbal supplements and methods of use thereof
TWI660748B (zh) 2013-03-01 2019-06-01 日商大塚製藥股份有限公司 用於口服投藥之包含非晶型托伐普坦(Tolvaptan)的懸浮液
EP2978423A4 (en) 2013-03-28 2016-08-24 Bbs Nanotechnology Ltd STABLE NANO COMPOSITION WITH DOXORUBICIN, PROCESS FOR THE PREPARATION THEREOF, THE USE THEREOF AND PHARMACEUTICAL COMPOSITIONS THEREWITH
SG10201913730RA (en) 2013-04-12 2020-03-30 Rebecca Bent Cancer therapy
EP2989115A4 (en) 2013-04-26 2017-01-11 Nitto Denko Corporation A large scale process for preparing poly (glutamyl-glutamate) conjugates
US10398682B2 (en) 2013-07-15 2019-09-03 The Board Of Regents Of The University Of Texas System Methods and compositions to prevent or treat bacterial infections
JP2016069303A (ja) 2014-09-29 2016-05-09 タカラバイオ株式会社 フコイダンを有効成分とする脱毛抑制用組成物
ES2630106T3 (es) 2014-10-07 2017-08-18 Cyprumed Gmbh Formulaciones farmacéuticas para la administración oral de fármacos peptídicos o proteicos
WO2016057744A1 (en) 2014-10-08 2016-04-14 Synthetic Biologics, Inc. Beta-lactamase formulations and uses thereof
US20160122739A1 (en) 2014-10-31 2016-05-05 Wisconsin Alumni Research Foundation Factor ix variants and methods of use therefor
JP6716464B2 (ja) 2014-12-03 2020-07-01 ノーベルファーマ株式会社 酢酸亜鉛水和物錠及びその製造方法
US20200330557A1 (en) 2016-08-19 2020-10-22 Brooklyn Immunotherapeutics Llc Uses of pd-1/pd-l1 inhibitors and/or ctla-4 inhibitors with a biologic containing multiple cytokine components to treat cancer
SG10201609131YA (en) 2016-11-01 2018-06-28 Xylonix Ip Holdings Pte Ltd Zinc-pga compositions and methods for treating cancer
SG10201708886RA (en) 2017-10-30 2019-05-30 Xylonix Ip Holdings Pte Ltd α-PGA-ZINC COMPOSITIONS AND METHODS FOR TREATING CANCER
KR20210024065A (ko) 2018-06-22 2021-03-04 자일로닉스 아이피 홀딩스 피티이. 엘티디. 아연 제제를 이용한 종양학 치료

Similar Documents

Publication Publication Date Title
JP2019534330A5 (cg-RX-API-DMAC7.html)
CN103917231B (zh) 组蛋白脱乙酰酶抑制剂与苯达莫司汀的联合制剂及其用途
US20140030323A1 (en) Controlled release of n-acetylcysteine (nac) for reduction of systemic and/or vascular inflammation
US20200268692A1 (en) Methods for the treatment of cysteamine sensitive disorders
JP2016504384A5 (cg-RX-API-DMAC7.html)
JP2009215293A5 (cg-RX-API-DMAC7.html)
JP2013527224A5 (cg-RX-API-DMAC7.html)
JP7466822B2 (ja) 亜鉛-γ-PGA組成物およびがんを処置するための方法
WO2020239097A1 (zh) 一种parp抑制剂微丸制剂及其制备工艺
JP2016155826A (ja) 経口薬物療法のための方法および組成物
TW202214243A (zh) 西奧羅尼聯合免疫檢查點抑製劑在抗腫瘤治療中的應用
CN101686944A (zh) 熊去氧胆酸的高剂量组合物
JP2008533127A5 (cg-RX-API-DMAC7.html)
TWI447113B (zh) 醫藥組合
TWI399206B (zh) 抗腫瘤劑
JP2021501143A5 (cg-RX-API-DMAC7.html)
CN103327975A (zh) 用于治疗多形性成胶质母细胞瘤的含有马西替坦的组合物
CN106102744A (zh) 用于治疗异常细胞生长的组合物和方法
KR20210106477A (ko) 5-브로모피리딘-3-일 3-데옥시-3-[4-(3,4,5-트리플루오로페닐)-1h-1,2,3-트리아졸-1-일]-1-티오-알파-d-갈락토피라노사이드의 비정질 형태
RU2016116915A (ru) Комбинация
EP4331569A1 (en) Sorafenib or donafenib oral preparation with low dose and high drug exposure, and application thereof
JP7352541B2 (ja) がんを処置するためのアルファ-ポリグルタミン酸-亜鉛を含む組成物
PH12022552521A1 (en) A modified release multiple unit oral dosage form of doxylamine succinate and pyridoxine hydrochloride and a process for its preparation
JP2019534046A5 (cg-RX-API-DMAC7.html)
JP2014511850A5 (cg-RX-API-DMAC7.html)